Key facts
- It has raised $500K; the latest was Seed Round ($500K) in Jun 2025.
- Notable investors include BioAdvance Capital (Conshohocken), Hatch Biofund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for MasterSwitch Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for MasterSwitch Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MasterSwitch Bio
Developer of a modified messenger Ribonucleic Acid (mRNA) therapy designed to target master transcription regulators to reverse end-stage liver disease and cirrhosis. The company's core technology is a modified mRNA of HNF4α (hepatocyte nuclear factor-4 alpha), which is the master regulator of hepatocyte function that demonstrates complete reversal of disease and cirrhosis in rat, human hepatocyte, and explanted human liver models, enabling patients to restore core hepatocyte functions, reverse cirrhosis, resolve complications such as portal hypertension and inflammation, and achieve sustained correction of the cell's transcriptional network.
- Sector
- Healthcare
- HQ
- Ambler, PA, United States
- Founded
- 2024
- Employees
- 2
- Website
- masterswitchbio.com/
- Ownership
- Privately Held (backing)
MasterSwitch Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MasterSwitch Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MasterSwitch Bio in its N-PORT filings yet. We sweep new filings monthly.